Cargando…
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
This year the medical community was pleasantly surprised by the results of the first large outcome trial that primarily examined the renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (CANA) in subjects with diabetes and impaired kidney function. The Evaluation of th...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993196/ https://www.ncbi.nlm.nih.gov/pubmed/32003836 http://dx.doi.org/10.1093/ndt/gfz264 |